Phase 3 N=121 Heart Rate Reduction in Heart Failure
Heart Failure
Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,067 An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Rheumatoid Arthritis
Primary: Percentage of Participants With ≥ 1 Adverse Event — 96.3 Percentage of participants
Phase 3 N=92 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Phase 3 N=365 A Study to Compare a New Eye Drop Formulation With Refresh Contacts®
Contact Lens Lubrication
Primary: Percentage of Participants With Contact Lens Distance Visual Acuity Change From Baseline — 11.1; 10.7; 88.9; 88.4 percentage of participants
Phase 3 N=87 Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)
Perennial Allergic Rhinitis
Primary: Percentage of Participants Who Experience at Least One Adverse Event (AE) — 74.5; 55.6 Percentage of participants
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
Phase 3 N=676 PEARL Schizophrenia Maintenance
Schizophrenia
Primary: Time to First Relapse Event During Double-blind Phase — NA; 192 days — p=0.039
Phase 3 N=591 Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery
Cataract
Primary: The Primary Efficacy Variable is Response Based on the Realisation of the Capsulorhexis Without Use of Any Additive Mydriatic Treatment. — 98.9; 94.7 percentage of…
Phase 3 N=1,537 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134
Phase 3 N=180 A Study of Semagacestat for Alzheimer's Patients
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog11) at Week 16 After Cessation of Study Drug — 6.4; 12.5; 10.5 units on a scale
Phase 3 N=632 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL
Phase 3 N=130 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itching Score by Visit — -0.6; -0.9; -1.3; -1.7 score
Phase 3 N=764 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants
Phase 3 N=442 A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 7.86; 7.72; -0.20; -0.37 percent of HbA1c in blood — p=0.306